Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Lebanon Sci-Tech Weekly.
Press releases published on August 25, 2025
iBio Announces Closing of $50 Million Public Offering
Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and included participation from Cormorant Asset Management, Adage Capital Partners LP, Ally Bridge …
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms test results align with treatment decision-making …
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee
Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of Directors Research and Development Committee established to accelerate innovation and long-term growth Dr. Ken Takeshita appointed to the Scientific Advisory Board ROCKVILLE, Md., Aug. …
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its …
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that …
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines – – Substantial improvement in …
Golf Superstore Uses Descartes Sellercloud™ to Unify Omnichannel Operations
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Chattanooga-based Golf Superstore is using Descartes Sellercloud™ integrated …
Crafting Seamless Notifications: How EngageLab’s Chrome Extension WebPush Is Transforming User Engagement and Extension Efficiency
SINGAPORE, Aug. 25, 2025 (GLOBE NEWSWIRE) -- EngageLab launches industry-leading WebPush support for Chrome Extensions, empowering developers and businesses to reach users with real-time, high-impact notifications—no extra permissions, no missed …
Server PSU Supplier Linklieo Expands Global CRPS and Common Redundant Power Solutions
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Linklieo, a leading server power supply supplier, today announced the expansion of its advanced server PSU, server power supply, and CRPS power supply product lines. Known for delivering dependable and high- …
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmology Sebastian Wolf, M.D …
Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology
Total equity and debt raising of ~$90 million provides runway to 2H 2027 Strong support from existing and new investors including SPRIM Global Investments Funds will be used to scale-up production of needle-free vaccination delivery technology Founding CEO …
BetSymphony Unites Voice, AI, and Personalization to Create the First Conversational Frontend in iGaming
AMSTERDAM, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BetSymphony just raised the bar for iGaming. The no-revenue-share iGaming platform has introduced a next-generation Conversational AI interface, powered by its advanced AI agent BetHarmony, now delivering a …
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) …
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental Biologics License Application (sBLA) to …
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ®, citing four new reports …
Valneva annonce la décision de la FDA de suspendre la licence d’IXCHIQ® aux États-Unis
Saint Herblain (France), le 25 août, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que l’agence de santé américaine Food and Drug Administration (FDA) a suspendu la licence d’IXCHIQ®, …
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting New Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi …
OSE Immunotherapeutics Propose une Evolution de sa Gouvernance et Réaffirme ses Priorités Stratégiques à l’Approche de son Assemblée Générale Annuelle
OSE Immunotherapeutics Propose une Evolution de sa Gouvernance et Réaffirme ses Priorités Stratégiques à l’Approche de son Assemblée Générale Annuelle Une nouvelle structure du Conseil qui reflète une représentation équilibrée et proportionnée des …
Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related sector
- Expanding opportunities for organ transplantation worldwide and contributing to the advancement of transplant medicine - OXFORD, United Kingdom and MADISON, N.J., Aug. 24, 2025 (GLOBE NEWSWIRE) -- Terumo Corporation (TSE: 4543, “Terumo”) today announced …
HUTCHMED Announces Appointment of Acting Chief Executive Officer
HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his …